ImmunoGen Stock Forecast for 2023 - 2025 - 2030
Updated on 05/08/2024
ImmunoGen Stock Forecast and Price Target
The average price target for ImmunoGen's stock of $16.74 recently provided by six leading analysts would represent a -46.4% downside from its last closing price if reached. This potential increase is based on a high estimate of $18.75 and a low estimate of $14.90. If you're thinking of investing in IMGN stock, it's critical to check out its competitors as well.
-46.40% Downside
ImmunoGen Fair Value Forecast for 2023 - 2025 - 2030
In the last four years, ImmunoGen's Price has seen an increase, rising from $0.00 to $0.00. This represents a growth of 100.00%. Analysts predict that ImmunoGen's Fair Value will increase in the upcoming year, reaching $33.49. This would represent an increase of 100.00%. Over the next ten years, experts predict that ImmunoGen's Fair Value will grow at a rate of 100.00%.
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| ABBV Stock Forecast | AbbVie | Outperform |
9
|
$162.55 | Buy/Sell | $178.42 | 10.74% |
| AMGN Stock Forecast | Amgen | Outperform |
4
|
$300.30 | Buy/Sell | $303.65 | 6.56% |
| GILD Stock Forecast | Gilead Sciences Inc | Outperform |
11
|
$65.46 | Buy/Sell | $87.82 | 22.21% |
| ALXN Stock Forecast | Alexion Pharmaceuticals | - |
0
|
$182.50 | Buy/Sell | $177.38 | -100.00% |
| BIIB Stock Forecast | Biogen | Outperform |
10
|
$218.92 | Buy/Sell | $299.62 | 31.78% |
ImmunoGen Revenue Forecast for 2023 - 2025 - 2030
In the last two years, ImmunoGen's Revenue has fallen from $132.30M to $108.78M – a 17.78% decrease. Analysts predict that ImmunoGen's Revenue will increase in the upcoming year, reaching $539.52M. This would represent an increase of 395.97%. Over the next ten years, experts predict that ImmunoGen's Revenue will grow at a rate of 1209.04%.
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| BMRN Stock Forecast | BioMarin Pharmaceutical | Outperform |
10
|
$82.58 | Buy/Sell | $111.56 | 33.20% |
| INCY Stock Forecast | Incyte | Outperform |
9
|
$54.37 | Buy/Sell | $77.05 | 44.38% |
| VKTX Stock Forecast | Viking Therapeutics | Buy |
5
|
$79.61 | Buy/Sell | $34.00 | 44.45% |
.jpg)
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| BPMC Stock Forecast | Blueprint Medicines | Outperform |
6
|
$108.55 | Buy/Sell | $85.71 | 10.09% |
| ARNA Stock Forecast | Arena Pharmaceuticals | - |
6
|
$99.99 | Buy/Sell | $100.00 | -100.00% |
| CCXI Stock Forecast | ChemoCentryx | - |
8
|
$51.99 | Buy/Sell | $52.00 | -100.00% |
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| CBAY Stock Forecast | CymaBay Therapeutics | Hold |
8
|
$32.44 | Buy/Sell | $27.73 | -100.00% |
| IOVA Stock Forecast | Iovance Biotherapeutics | Buy |
4
|
$13.98 | Buy/Sell | $20.42 | 82.40% |
| ARWR Stock Forecast | Arrowhead Pharmaceuticals | Outperform |
7
|
$25.00 | Buy/Sell | $52.00 | 120.00% |
ImmunoGen EBITDA Forecast for 2023 - 2025 - 2030
ImmunoGen's EBITDA has grown in the last two years, jumping from $-18.79M to $-219.11M – an increase of 1066.10%. For the following year, the 1 analysts predict that ImmunoGen's EBITDA will drop by 119.40%, reaching $42.50M. In 2030, the professionals' prediction is that IMGN's EBITDA will decrease by 294.76%, reaching $426.73M.
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| DRNA Stock Forecast | Dicerna Pharmaceuticals | - |
7
|
$38.01 | Buy/Sell | $35.06 | -100.00% |
| FOLD Stock Forecast | Amicus Therapeutics | Outperform |
7
|
$10.42 | Buy/Sell | $17.90 | 91.94% |
| ACAD Stock Forecast | ACADIA Pharmaceuticals | Outperform |
6
|
$17.25 | Buy/Sell | $33.78 | 73.91% |
ImmunoGen EBIT Forecast for 2023 - 2025 - 2030
In the last two years, ImmunoGen's EBIT has increased by 957.40%, going from $-20.89M to $-220.89M. In the following year, the 13 analysts surveyed believe that ImmunoGen's EBIT will decrease by 151.58%, reaching $113.93M. According to professionals, by 2030, ImmunoGen's EBIT will have decreased by 463.83%, falling down to $803.66M.
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| CLDX Stock Forecast | Celldex Therapeutics | Buy |
11
|
$42.21 | Buy/Sell | $63.29 | 68.21% |
| VCEL Stock Forecast | Vericel | Buy |
8
|
$49.52 | Buy/Sell | $42.58 | 11.07% |
| ARDX Stock Forecast | Ardelyx | Buy |
11
|
$9.31 | Buy/Sell | $9.94 | 50.38% |
ImmunoGen EPS Price Prediction Forecast for 2023 - 2025 - 2030
In the last four years, ImmunoGen's EPS has seen an increase, rising from $-0.25 to $0.00. This represents a growth of 100.00%. Analysts predict that ImmunoGen's EPS will increase in the upcoming year, reaching $0.36. This would represent an increase of 100.00%. Over the next ten years, experts predict that ImmunoGen's EPS will grow at a rate of 100.00%.
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| AGIO Stock Forecast | Agios Pharmaceuticals | Outperform |
9
|
$32.80 | Buy/Sell | $40.00 | 35.67% |
| DVAX Stock Forecast | Dynavax Technologies | Outperform |
11
|
$11.76 | Buy/Sell | $25.00 | 108.33% |
| ADMA Stock Forecast | ADMA Biologics | Buy |
9
|
$6.91 | Buy/Sell | $6.00 | 15.77% |
.jpg)